Previous Article | Next Article ![]()
Journal of Clinical Microbiology, August 2006, p. 2838-2843, Vol. 44, No. 8
0095-1137/06/$08.00+0 doi:10.1128/JCM.00156-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, Brazil,1 Laboratório de Bacteriologia, Instituto Adolfo Lutz, São Paulo, Brazil,2 Centro de Biotecnologia, Instituto Butantan, São Paulo, Brazil3
Received 4 January 2006/ Returned for modification 6 March 2006/ Accepted 11 May 2006
|
|
|---|
|
|
|---|
The seven-valent polysaccharide-protein conjugate vaccine has been shown to be efficacious against invasive pneumococcal diseases (5); however, protection is limited to those serotypes included in the vaccine formulation. Furthermore, replacement by nonvaccine serotypes has been described following the introduction of mass immunization (4), and the vaccine has not achieved the desired success in reducing colonization by vaccine-related serotypes (18). Recently, Dagan et al. (12) demonstrated that a nine-valent pneumococcal conjugate vaccine was able to elicit a systemic humoral immune response which reduced the carriage rate by prevention of the new acquisition of S. pneumoniae but has no effect on the duration of carriage once a serotype is acquired. The low serotype coverage and the high cost of the pneumococcal conjugate vaccines have hampered their implementation, especially in developing countries, and have prompted researchers to investigate pneumococcal protein antigens as components of vaccines which could protect against multiple serotypes at lower costs.
Pneumococcal surface protein A (PspA) is a recognized virulence factor expressed by all pneumococcal isolates. In animal models, PspA is able to elicit a protective immune response against pneumococci with different capsular serotypes (7, 21, 22). There is evidence that protective epitopes reside in the amino-terminal portion of PspA. Differences in reactivity determined by the use of several monoclonal antibodies point to the complex and serological diversity of PspA (9). In 2000, Hollingshead et al. (17) investigated the genetic basis for the serological diversity of PspA; and using the divergence of the N-terminal
-helical region of pspA nucleotide sequences, the authors identified three families of pspA (cutoff value, 40%). The main region responsible for the diversity among PspAs comprises a sequence of approximately 100 amino acids located at the end of the
-helical N-terminal region, known as the clade-defining region. Analysis of this region further subdivided the families into clades that diverged from each other by over 20% and showed that PspAs within the same clade had greater than 90% identity. Thus, according to its genetic diversity, PspA has been classified into family 1 (Fam1; clades 1 and 2), family 2 (Fam2; clades 3, 4, and 5), and family 3 (Fam3; clade 6).
Immunization of humans with PspA has induced broadly cross-reacting antibodies to heterologous PspAs, and the cross-clade reactivity roughly follows the degree of similarity among the sequences, with a tendency for a higher degree of cross-reactivity among PspAs within the same family (24). Briles et al. (10) demonstrated that sera from PspA-immunized individuals protect mice from fatal infection with S. pneumoniae expressing PspAs of different families. Studies of the local and systemic immune responses against PspA have raised evidence that antibodies to PspA could prevent NP colonization in humans and mice (20, 25). Thus, on the basis of its immunogenic properties, PspA could be an alternative antigen in a vaccine formulation aimed at attaining a strong impact on the prevention of pneumococcal NP colonization, in addition to protecting against invasive disease.
In order to establish the possible use of PspA as a vaccine candidate antigen, it is crucial to know the total array of PspAs expressed in pneumococcal strains in the community. Few studies have investigated the genetic diversity of PspA (15, 23, 26, 27), and scarce information focusing on PspA from strains derived from carriage pneumococci has been published (8). We therefore conducted this study to investigate the PspA families and clades collected from nasopharyngeal carriage isolates of community-acquired S. pneumoniae in children during an ongoing surveillance. We have also examined the clade-defining region of PspAs obtained from NP and have underscored the degree of similarity among them. These are pivotal issues in pursuing a potential pneumococcal vaccine candidate which would protect against all pneumococcal isolates, regardless of their serotype.
|
|
|---|
During the surveillance period, a total of 232 NP pneumococcal isolates were obtained. For this study, in order to determine the array of PspA types colonizing the nasopharynges of children, 183 (79%) S. pneumoniae isolates were typed from children with respiratory tract infections (n = 48), pneumonia (n = 33), or meningitis (n = 5) and also from healthy children (n = 97). Written informed consent was obtained from the parents or the guardians of the children. The study protocol was approved by the regional and national ethical committees.
Collection of NP swabs and microbiological analysis. The technical procedures used for NP swab collection, specimen transport, storage, and culture of the samples followed the standard procedures for the detection of upper respiratory tract carriage of S. pneumoniae (28). The NP specimen was collected with a pernasal, extrathin, flexible, calcium alginate swab; placed in Stuart transport medium tubes (Transwab; Medical Wire & Equipment, Whiltshire, United Kingdom); and transported to the Laboratory of Bacteriology of the Federal University of Goiás. S. pneumoniae strains were identified by their colony appearance, alpha-hemolysis, morphology in Gram stain, optochin susceptibility, and the bile solubility test. Susceptibility tests were first performed by the disk diffusion method with Oxoid (Basingstoke, United Kingdom) disks, and the penicillin MICs for the penicillin-nonsusceptible pneumococci (PNSp) were determined by broth microdilution. The results were interpreted according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI; formerly the National Committee for Clinical Laboratory Standards) (11). Pneumococcal serotyping was performed at the Instituto Adolfo Lutz, São Paulo, Brazil, by use of the Quellung reaction with sera produced by the Statens Seruminstitut, Copenhagen, Denmark.
PspA typing by PCR and sequencing. The bacterial cell suspension from the pneumococci isolates was prepared from 5 ml of Todd-Hewitt liquid medium containing 0.5% yeast extract (THY), in which they had been incubated overnight at 37°C. The cultures were centrifuged and resuspended in 200 µl of THY and 20% glycerol. The suspension was stored at 20°C until it was tested. DNA standards from strains Rx1 (clade 2) and BG11703 (clade 4) were used as controls for Fam1 and Fam2, respectively, in each set of PCRs. The PCR was performed with oligonucleotide primers synthesized on the basis of the published DNA sequences for PspA Fam1 (primers LSM12 and SKH63); PspA Fam2 (primers LSM12 and SKH52); and PspA Fam1, Fam2, and Fam3 (primers LSM12 and SKH2) (15, 26). The volume of the PCR mixture was 25 µl and contained PCR buffer, 3.5 mM MgCl2, 200 µM deoxyribonucleotides, 50 pmol of each primer, and 1 U of recombinant Taq polymerase (Invitrogen). A volume of 2 µl of cell suspension was used as the template. The DNA amplification (MJ Research Inc.) with primer sets LSM12/SKH63 and LSM12/SKH52 was carried out under the following conditions: an initial cycle of 94°C (10 min) and then 30 cycles of 94°C (1 min), 62°C (1 min), and 72°C (3 min), followed by a cycle of 72°C (7 min). The PCR products were resolved by electrophoresis on a 1% agarose gel for 1 h at 120 V. The gels were stained with ethidium bromide and photographed under UV light. This first set of PCRs allowed the classification of strains into PspA Fam1 or Fam2. Another PCR was performed with oligonucleotide primers LSM12 and SKH2, with the annealing temperature decreased to 58°C (15). This second PCR should amplify pspA from all strains, including Fam3. The two sets of PCRs for pneumococcal isolates and for DNA standards showed consistent results for families (Fam1 and Fam2) and clades. After three PCR attempts, pneumococcal strains which were PCR negative by LSM12/SKH2 amplification were considered nontypeable. The PCR products from primer set LSM12/SKH2 were purified from agarose gels (GFX PCR DNA and Gel Band purification kit; Amersham Biosciences) for direct sequencing by using SKH2 as the primer. Automated sequencing reactions used dye terminator chemistry, and the sequences were analyzed with a model 3100 genetic analyzer (Applied Biosytems). The DNA sequences generated were submitted to GenBank, analyzed with the Chromas program, and submitted to analysis with the ORF (open reading frame) Finder. The predicted amino acid sequence was searched against the sequence database by using BLAST software (www.ncbi.nlm.nhi.gov/BLAST) (1).
Data analysis. Descriptive analysis was performed with EpiInfo software (version 6.04; Centers for Diseases Control and Prevention, Atlanta, GA). Differences in proportion were compared by the chi-square test or Fisher's exact test, when appropriate. P values less than 0.05 were considered statistically significant. The prevalence and the corresponding 95% confidence interval were calculated.
The diversity of pspA (clades 1 to 6) was analyzed by comparing the predicted amino acid sequences found for NP pneumococcal strains with those amino acid sequences of the clade-defining region of 24 invasive reference sequences retrieved from GenBank (accession numbers AF071802 to AF071818, AF071820, AF071821, AF071823, AF071824, AF071826, U89711, and M74122) (17). The phylogenetic analysis was also done with the DNA sequences, and the corresponding dendrogram was compared to the one generated with the nucleotide sequences. The analysis of the genetic relatedness among PspAs was done with BioNumerics software (v 4.0; Applied Maths, Sint-Martens-Latem, Belgium). Cluster analyses with Pearson's coefficient and the hierarchical unweighted pair group method (UPGMA) were performed to generate a dendrogram of the relationship between clade-defining region B of the PspAs of the NP strains and the invasive reference strains. The UPGMA dendrogram prevails on the assumption that amino acid substitution rates are the same across all branches. This methodology uses a sequential clustering algorithm, in which local topological relationships are identified in order of similarity and the tree is built in a stepwise manner. A total of 1,000 bootstrap replicates were performed and bootstrap values equal to or greater than 95% were considered significant, whereas values from 70 to 94% were considered moderately significant.
Nucleotide sequence accession numbers. The DNA sequences generated in this study have been submitted to GenBank (accession numbers DQ459217 to DQ459257).
|
|
|---|
|
View this table: [in a new window] |
TABLE 1. PspA families and clades of 183 S. pneumoniae isolates from nasopharynges of children
|
|
View this table: [in a new window] |
TABLE 2. Nasopharyngeal PspA clades by clinical status of 183 children
|
![]() View larger version (22K): [in a new window] |
FIG. 1. Frequencies of nasopharyngeal PspA clades by capsular serotypes (A) and by penicillin susceptibility (B). Ninety nasopharyngeal pneumococcal isolates were investigated for their capsular serotypes by the Quellung reaction with sera from the Statens Seruminstitut, and PspA clades were investigated by PCR with oligonucleotide primers synthesized on the basis of the published DNA sequences for PspA Fam1 (primers LSM12 and SKH63) and PspA Fam2 (primers LSM12 and SKH52). The distribution of the PspA clades among the most frequent serotypes is shown in panel A. One hundred thirty-eight NP pneumococcal strains were investigated for their PspA clades by PCR and for their susceptibilities to penicillin by determination of the penicillin MIC by broth microdilution, with interpretation of the results by use of the criteria of CLSI. The distribution of PspA clades 1 to 5 among pneumococcal susceptible and nonsusceptible to penicillin is presented in panel B, and no significant difference (P < 0.05) was found when the susceptible and nonsusceptible NP pneumococcal strains in clades 1 to 4 were compared.
|
![]() View larger version (19K): [in a new window] |
FIG. 2. Dendrogram derived from comparison of 40 PspA-deduced amino acid sequences of nasopharyngeal strains and 24 sequences of PspA invasive reference strains (GenBank accession numbers AF071802 to AF071818, AF071820, AF071821, AF071823, AF071824, AF071826, U89711, and M74122). The dendrogram was constructed by using BioNumerics software (v 4.0). The names of the NP strains are indicated to the right of each branch point of the tree. Strain M98, marked with an asterisk, represents an invasive pneumococcal isolate from the blood of a child with meningitis. The invasive reference strains are boxed. Pearson's coefficient and the UPGMA clustering method were used for the analysis. Bootstrap values based on 1,000 replicates (in parentheses) and the percentages of similarity are distinguished for important nodes. The PspA families are represented by the gray column next to the corresponding clades.
|
|
|
|---|
Concerning all NP pneumococcal isolates, the clades of PspA Fam1 and Fam2, except for clade 5, were detected at similar frequencies; clade 5 was rarely detected. These findings are in accordance with those of previous reports on invasive pneumococcal strains, in which the prevalence of PspA Fam1 ranged from 44.8 to 51.9% and that of Fam2 ranged from 43.2 to 55.2% (3, 8, 26). However, the predominance of PspA Fam1 (15, 17, 27) and the high prevalence of PspA Fam2 (85.7%) have been detected in some studies (2), mainly with adult populations. While a low proportion of nontypeable PspA has been detected among invasive pneumococcal strains, as reported in the literature (8, 16), we have found a high frequency of NP nontypeable PspA strains (20.2%), as has also been described in a previous study in Brazil, in which PspA could not be typed for 16.6% of the nasopharyngeal strains (8). Although PCR was performed three times and different strategies were tested, including pooling of cultures, amplification was not successful. In this carriage study, the nontypeable PspAs were mainly derived from serotype 10A strains, which grew poorly in cultures. Another strategy would be necessary to overcome this limitation in order to ascertain the PspA for this serotype, since pneumococcal serotype 10A is prevalent in NP carriers in our setting (19).
Our results showed no statistically significant difference between the prevalence of NP PspA families and clades in healthy and ill children, as recently reported in studies that were conducted with invasive pneumococcal isolates and that compared patients with and without sickle cell disease (26). Therefore, we could hypothesize a similar prevalence of PspA types in NP pneumococcal colonizers and invasive strains, reinforcing the usefulness of PspA as a promising candidate for the pneumococcal vaccine. The resistance to penicillin did not differ significantly among the NP pneumococcal strains expressing Fam1 and Fam2 or even clades 1, 2, 3, or 4, although in the previous study in Brazil, a significant tendency for the association of invasive PNSp strains with Fam2 was observed over the years (8). However, for unknown reasons, we found a high frequency of PspA Fam1, clade 2, in PNSp strains. Additional studies in Brazil and other countries could clarify these aspects. The NP PspA distribution was independent of the serotypes, which emphasizes the potential role of PspA as a vaccine antigen candidate that could induce protection against all S. pneumoniae serotypes.
The PspA dendrogram generated by grouping together the PspA sequences of NP and invasive reference strains closely reproduced the profiles of the families and clades reported by Hollingshead et al. (17). The families and clades were separated by divergences of over 40% and 20%, respectively. Clade 5 was more divergent from the other clades of Fam2, as reported previously (3, 17). As expected, most of the PspA sequences from NP or invasive strains presented over 90% similarity within the same clade; the exception was invasive strain M98, which diverged more than 20% from the invasive reference strain ATCC 6303 from clade 5. We are aware that only 40 of 146 PspA sequences entered into the dendrogram, and therefore, one could argue whether these strains are representative. However, since the 40 complete sequences of the PspA NP strains matched the 24 PspA sequences of the invasive strains, our assumption was that the alignment of the 146 PspA sequences would probably be similar.
Therefore, according to the diversity of the PspAs expressed by circulating NP pneumococcal strains in the community in Brazilian children, it is conceivable to anticipate that the degree of antibody cross-reactivity and/or cross-protection against different NP strains could be satisfactory and could prevent pneumococcal carriage. Furthermore, the data highlight the picture of the NP PspA array in relation to some invasive reference PspAs, indicating that these sequences share epitopes which could induce cross-immunity. The results strengthen the idea that the use of PspA, irrespective of whether it is derived from NP or invasive related strains, may protect children against carriage as well as invasive pneumococcal disease.
We thank Leonardo S. Kobashi for PspA sequence analysis.
|
|
|---|
-helical domain of PspA elicits protective immunity against Streptococcus pneumoniae. Infect. Immun. 69:5456-5463.This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»